PMS2 and adenoma: There was no statistically significant difference in the prevalence of adenomas in path_MLH1 versus path_MSH2 carriers but both path_MSH6 and path_ PMS2 carriers were significantly less likely to have any adenomas than were path_MLH1 or path_MSH2 carriers (p < 0.001).